Semantic Scholar uses AI to extract papers important to this topic.
BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin… Expand We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids… Expand BACKGROUND
Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol… Expand Objective—To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on… Expand Systematic identification of protein-drug interaction networks is crucial to correlate complex modes of drug action to clinical… Expand BACKGROUND
High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular risk. Cholesteryl… Expand BACKGROUND
Residual cardiovascular (CV) risk often remains high despite statin therapy to lower low-density lipoprotein… Expand Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL… Expand Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high… Expand BACKGROUND
The inhibition of cholesteryl ester transfer protein (CETP) is considered a potential new mechanism for treatment of… Expand